Clinical Study on Budesonide Combined with Montelukast in Treatment of Mycoplasma Pneumonia of Children
Objective To explore effect of budesonide combined with montelukast in treatment of pediatric mycoplasma pneumonia.Methods The paper chose 95 children with mycoplasma pneumoniae pneumonia admitted to our hospital from February 2018 to February 2023 as data analysis objects,and divided them into two groups:control group(n=47)and observation group(n=48)with digital randomization method.Control group was treated with budesonide treatment,while observation group with montelukast treatment on the basis of control group.Clinical effect,clinical indicators,incidence of adverse reactions and levels of inflammatory factors were compared between two groups.Results Comparison of treatment effect between two groups showed observation group accounted for 97.92%,while control group accounted for 87.23%,that of observation group was significantly higher than control group(P<0.05).Two clinical indicators were compared between two groups.After treatment,observation group had significantly shorter time of returning normal body temperature(1.38±0.39)days,cough disappearance time(6.09±1.51)days,wheezing disappearance time(4.21±1.01)days,and wet rale disappearance time(4.69±1.10)days than control group,with significant difference(P<0.05).There was no significant difference in incidence of adverse reactions between two groups(P>0.05).Comparison of levels of inflammatory factors showed,namely white blood cell count(WBC)and C-reactive protein(CRP),WBC was(6.43±1.70)* 109/L and CRP was(2.19±1.64)μg/L in observation group,significantly lower than control group(P<0.05).Conclusion Combination of budesonide and montelukast can achieve significant effect and high safety in treatment of mycoplasma pneumonia of children,which is worthy of promotion and application in a large scale in clinical treatment.
BudesonideMonlustMycoplasma pneumonia of childrenCurative effectAdverse reactions
万方数据
维普
